Novo Nordisk plans to invest DKK 500m in expanding tablet production facilities

Wishing to generate further capacity for the future production of diabetes tablet Rybelsus, Novo Nordisk plans to invest DKK 500m in an expansion of the company's production facilities in Denmark.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Danish pharmaceutical company Novo Nordisk plans to invest DKK 500m in expanding the company's production facilities near Copenhagen in Denmark, informs the company in a press release Thursday morning.

According to the company, this is to ensure the company's production capacity for the diabetes drug Rybelsus, which is based on the molecule semaglutide.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs